REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Chemistry: Molecular Biology And Microbiology > Vector, Per Se (e.g., Plasmid, Hybrid Plasmid, Cosmid, Viral Vector, Bacteriophage Vector, Etc.) Bacteriophage Vector, Etc.) Vector, Per Se (e.g., Plasmid, Hybrid Plasmid, Cosmid, Viral Vector, Bacteriophage Vector, Etc.) Bacteriophage Vector, Etc.)Vector, Per Se (e.g., Plasmid, Hybrid Plasmid, Cosmid, Viral Vector, Bacteriophage Vector, Etc.) Bacteriophage Vector, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.04/19/07 - 20070087433 - Metabolically activated recombinant viral vectors and methods for their preparation and use Recombinant viral vectors, especially parvovirus vectors such as adeno-associated virus (AAV) vectors, capable of enhanced expression of heterologous sequences, and methods for their construction and use, are provided. The vectors have a structure, or are capable of rapidly adopting a structure, which involves intrastrand base pairing of at least one ... 04/19/07 - 20070087432 - Smallpox vaccine series 77 Herpes is treated by administering a smallpox vaccination and by repeatedly administering the vaccination after waiting a scab, formed after a blister at the vaccination site, falls off, with the treatment being completed when the blister and scab fail to form. ... 04/12/07 - 20070082391 - Modified cea nucleic acid and expression vectors The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One ... 03/15/07 - 20070059820 - Methods to express recombinant proteins from lentiviral vectors Lentivector constructs for expression of recombinant proteins, polypeptides or fragments thereof and methods of making the same are described. The lentivectors typically have a self-processing cleavage sequence between a first and second protein or polypeptide coding sequence allowing for expression of a functional protein or polypeptide under operative control of ... 03/08/07 - 20070054395 - Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 ... 03/08/07 - 20070054394 - Recombinant protein production in a human cell Methods and compositions for the production of recombinant proteins in a human cell line. The methods and compositions are particularly useful for generating stable expression of human recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts ... 03/01/07 - 20070048862 - Vectors based on recombinant defective viral genomes and their use in the formulation of vaccines The vectors comprise a recombinant defective viral genome expressing at least one antigen suitable for the induction of systemic and secretory immune responses or an antibody conferring protection against an infectious agent. The defective viral genome comprises the genome of a parental virus having the viral replicase recognition signals located ... 03/01/07 - 20070048861 - Compositions and methods for generating an immune response The present invention relates to novel plasmid constructs useful for the delivery of DNA vaccines. The present invention provides novel plasmids having a transcription cassette capable of directing the expression of a vaccine nucleic acid insert encoding immunogens derived from any pathogen, including fungi, bacteria and viruses. The present invention, ... 03/01/07 - 20070048860 - Carcinoembryonic antigen (cea) peptides The present invention relates to novel modified CEA agonist (or antagonist) peptides, polypeptides and proteins containing a modified epitope therein, nucleic acids coding therefor, vectors comprising said nucleic acids, mixtures and compositions of the aforementioned agents, and their advantageous use in generating CEA-specific immune responses and/or in the treatment of ... 12/28/06 - 20060292687 - Methods for modulating floral organ identity, modulating floral organ number, increasing of meristem size, and delaying flowering time This invention is directed to plant genetic engineering. In particular, it relates to, for example, modulating seed (and in particular endosperm, embryo and seed coat) development, flowering time, chromosomal DNA methylation and modulating transcription in plants. ... 12/07/06 - 20060275897 - Hiv vaccines based on env of multiple clades of hiv In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a singlr clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another ... 09/14/06 - 20060205067 - Compositions and methods for enhancing the immunogenicity of antigens The present invention includes compositions, methods and kits for enhancing the immunogenicity of an antigen via fusion to a Listerial protein. The present invention further encompasses Listeria vaccine strains for enhancing the immunogenicity of an antigen. ... 08/31/06 - 20060194311 - Lna-cpg conjugates The present invention relates to novel compositions comprising DNA attached to an immunostimulatory oligonucleotide (CpG) via a locked nucleic acid oligonucleotide of a defined sequence. In particular the present invention provides compositions comprising a plasmid containing a gene encoding a protein of interest, wherein said plasmid may be introduced to ... 08/24/06 - 20060188981 - Mn gene and protein Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular contacts. The MN protein binding site is a therapeutic target that can be blocked ... 08/03/06 - 20060172413 - Transgenic mice containing melanocyte stimulating hormone receptor gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in melanocyte stimulating hormone receptor genes. Such transgenic mice are useful as models for disease and for identifying agents that modulate ... 07/27/06 - 20060166359 - Transgenic mice containing lumulus clotting factor protease-like gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a limulus clotting factor protease-like gene. Such transgenic mice are useful as models for disease and for identifying agents that ... 07/20/06 - 20060160211 - Transgenic mice containing, cgmp phosphodiesterase gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in cGMP phosphodiesterase genes. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression ... 07/06/06 - 20060148073 - Enhancement of adenoviral oncolytic activity in prostate cells by modification of the e1a gene product The present invention relates to compositions and methods for enhancing the oncolytic activity of replication-competent, target cell-specific adenovirus vectors by modification of the E1A gene product. The target cell-specific replication-competent adenovirus vectors comprise a chimera of an adenovirus gene essential for replication, preferably an early gene, and the Androgen receptor ... 06/22/06 - 20060134778 - Method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis There are provided methods for treatment of abnormal cells such as cancer cells in a mammal. The methods involve treating the mammal with virus selected from echoviruses and modified forms and combination thereof, which recognise α2β1 for infectivity of the cells. There are also provided methods for screening viruses for ... 06/08/06 - 20060121604 - Methods and materials for expression of a recombinant protein Recombinant expression vectors are provided comprising a 3′ UTR of a light chain and an Epstein-Barr virus origin of replication. Also provided are host cells comprising such vectors and methods of producing recombinant protein with such vectors. Additional methods of producing a recombinant protein involve contacting cells with a first ... 05/25/06 - 20060110823 - Transgenic mice containing glucocorticoid-induced receptor gene disruptions The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a glucocorticoid-induced receptor gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene ... 05/18/06 - 20060105451 - Genetically engineered p30 antigen improved antigen cocktail, and uses thereof The present invention relates to a genetically engineered P30 antigen and a combination or mixture of antigens (e.g., the genetically engineered P30 antigen and P35) that may be used in the detection of IgM and/or IgG antibodies to Toxoplasma gondii. Furthermore, the present invention also relates to methods of using ... 04/27/06 - 20060088932 - Gsk3 polypeptides The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of ... 04/06/06 - 20060073586 - Dna sequences encoding dystrophin minigenes and methods of use thereof The present invention provides a series of novel dystrophin minigenes that retain the essential biological functions. The expression of the dystrophin minigenes may be controlled by a regulatory element along with a small polyadenylation signal. The entire gene expression cassettes may be readily packaged into a viral vector, preferably an ... 03/30/06 - 20060068493 - Protein activity screening of clones having dna from uncultivated microorganisms Disclosed is a process of screening clones having DNA from an uncultivated microorganism for a specified protein, e.g. enzyme, activity by screening for a specified protein, e.g. enzyme, activity in a library of clones prepared by (i) recovering DNA from a DNA population derived from at least one uncultivated microorganism; ... 03/16/06 - 20060057714 - Vector The present invention provides a vector which can make nucleic acids to be an aggregate and locate a vector containing a cationic polymer to surround the aggregate so as to protect the nucleic acids from the enzyme. The vector comprises a polymer having branched chain(s). Preferably, 3, 4, or 6 ... 03/09/06 - 20060051859 - Long acting human interferon analogs Compositions, kits and methods are provided for Interferon analogs in order to promote general health or for therapeutic treatment of diseases. Human interferon analogs are made by fusion of interferon with human serum albumin. The bio-assay shows that the interferon analogs with the same cell protection against viral attack have ... 02/23/06 - 20060040382 - Tagged epitope protein transposable element A transposable element is provided that has a 3′ and a 5′ end. The transposable element includes a 5′ recombining site 5′ of a nucleic acid sequence encoding a selectable marker, a 3′ recombining site 3′ of the nucleic acid sequence encoding a selectable marker, a nucleic acid sequence encoding ... 02/16/06 - 20060035371 - Hybrid adeno-retroviral vector for the transfection of cells An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5′ retroviral LTR nucleic acid sequence, a 3′ retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5′ LTR or the 3′ LTR nucleic ... 02/02/06 - 20060024821 - Rolling circle replicon expression vector A rolling circle DNA replicon which replicates in a host eukaryotic cell is disclosed which has a truncated replication cycle. The rolling circle DNA replicon comprises the following elements present on the same DNA molecule. It contains a Rep gene open reading frame from a virus belonging to the viral ... 02/02/06 - 20060024820 - Chromosome-based platforms Artificial chromosomes, including ACes, that have been engineered to contain available sites for site-specific, recombination-directed integration of DNA of interest are provided. These artificial chromosomes permit tractable, efficient, rational engineering of the chromosome for a variety of applications. ... 02/02/06 - 20060024819 - Integration vectors The invention relates to integration vectors for modifying a target genomic region comprising, in a 5′ to 3′ direction, a splice acceptor site, a 3′ hybrid recognition site, and a marker sequence (i.e., a 5′ gene trap vector); or alternatively comprising, in a 5′ to 3′ direction, a marker sequence; ... 01/26/06 - 20060019382 - Transcriptionally-activated aav inverted terminal repeats (itrs) for use with recombinant aav vectors This invention provides transcriptionally-activated AAV ITRs (inverted terminal repeats) which are small and transcriptionally active and uses thereof to optimize the expression of relatively large transgenes packaged in recombinant AAV vectors. ... 01/26/06 - 20060019381 - Hyperthermic inducible expression vectors for gene therapy and methods of use thereof Methods and compositions are provided for transgene expression in target cells. Expression constructs using an inducible amplification system to drive expression of a therapeutic gene or other gene of interest in mammalian host cells are provided, as well as methods therefor. Inducible expression of the transgenes at high levels under ... 01/26/06 - 20060019380 - Genetic vaccines directed against bacterial exotoxins The invention provides a gene transfer vector comprising a humanized nucleic acid sequence encoding an immunogenic portion of one or more exotoxins of Bacillus anthracis and a heterologous sorting signal. The invention also provides a method of producing an immune response against Bacillus anthracis in a host comprising administering to ... 01/19/06 - 20060014276 - Chimeric adenoviruses The present invention provides methods and vector systems for the generation of chimeric recombinant adenoviruses. These hybrid adenoviruses contain a genome that is derived from different adenovirus serotypes. In particular, novel hybrid adenoviruses are disclosed with improved properties for gene therapy purposes. These properties include: a decreased sensitivity towards neutralizing ... 12/29/05 - 20050287662 - Helper-free stocks of recombinant adeno-associated virus vectors The present invention relates to a method for producing helper-free stocks of recombinant adeno-associated virus (rAAV) which can be used to efficiently and stably transduce foreign genes into host cells or organisms. The method comprises the cotransfection of eukaryotic cells with rAAV and with helper AAV DNA in the presence ... 12/01/05 - 20050266550 - Tc-83-derived alphavirus vectors, particles and methods The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower ... 12/01/05 - 20050266549 - Molecular switch for regulating mammalian gene expression Expression vectors are disclosed that are comprised of (a) one or more silencer elements and conditionally inducible elements to form silencer-inducible regions and (b) promoters in operative linkage upstream of at least one expressed region. The expression vector thereby regulates expression of at least one downstream region by conditional silencing ... 11/24/05 - 20050260746 - Transgenic pig containing heat shock protein 70 transgene The invention provides a transgenic pig having incorporated into its genome a HSP70 gene or fragment thereof, whereby said transgenic pig overexpresses HSP70. The transgenic pig of the invention can be used in the production of HSP in large quantities, as a xenograft source for transplation and as an animal ... 10/06/05 - 20050221474 - Gene promoters The invention is directed to a method for obtaining a promoter from an organism using a proteomics approach, isolated promoters from fungal species and uses of the isolated promoters. ... 06/30/05 - 20050142657 - Expression vector for the production of annexin v The invention relates to an expression vector comprising at least those components of the vectors pBR322 or pKK223-3, necessary for the replication thereof, an expression region sequentially comprising, in the reading direction, a first promotor, a binding site specific for a repressor, a sequence corresponding to a prokaryotic ribosome binding ... ### FreshPatents.com Support |